Newsroom | 97658 results

RALEIGH, N.C.--(BUSINESS WIRE)--Caidya: COO Announcement Press Release: China & Taiwan...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025. “This is a seminal moment for Vir Biotechnology, marked by key high-potential partnerships on two of our programs showcasing the strength of our pipeline and technology platforms. Today, we announced a global strategic collaboration with Astellas and compelling new Phase 1 data for VIR-5500, demonstr...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN® dual-masked T-cell engager (TCE) being evaluated in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have progressed after multiple lines of therapy (NCT05997615). These data suggest that VIR-5500 monotherapy is well tolerated and exhibits promising an...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases, today announced a new analysis of efficacy and biomarker data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in late-line metastatic clear cell renal cell carcinoma (ccRCC) from the Phase 1/1b ARC-20 study. These data will be presented in a post...

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the American Society of Genitourinary Cancers Symposium happening from February 26-28, 2026, in San Francisco, California. Flatiron's real-world data and research capabilities are featured across multiple presentations, including 6 research acceptances spanning genitourinary cancers. A cornerstone of Flatiron’s presence at ASCO GU 2026 is the global prostate cancer and bladder cancer Panoramic datasets, which draw from o...

米ニュージャージー州ジャージーシティ--(BUSINESS WIRE)--（ビジネスワイヤ） -- より健康な毎日のために効果的な医薬品とソリューションの提供を使命に掲げるグローバルヘルスケア企業のオルガノン（NYSE：OGN）は本日、セベラ・ファーマシューティカルズのホルモンフリー銅製子宮内避妊具（IUD）であるMIUDELLAについて、世界における権利を独占的にライセンスする契約を締結したと発表しました。本取引の成立は、ハート・スコット・ロディーノ反トラスト改正法（HSR法）に基づく審査、およびMIUDELLAの代替サプライチェーンに関わる事業体の承認を含む米国食品医薬品局（FDA）による承認、その他一定の条件を満たすことを前提としています。 過去40年で米国において承認された初のホルモンフリー銅製IUDであるMIUDELLAはオルガノンの商業展開力と補完関係にあり、女性の多様なリプロダクティブ・ヘルス（生殖に関する健康）ニーズに応える製品ポートフォリオの構築に向けたオルガノンの取り組みをさらに推進します。MIUDELLAは2025年2月24日にFDAより承認を取得しており、妊娠...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced interim data from its Proof-of-Concept Phase 1/2 ANQUR clinical trial of QRL-201 in people living with amyotrophic lateral sclerosis (ALS). Results from this study demonstrated QRL-201 had an effect on disease pro...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference on Monday, Mar. 9, 2026. The Company's presentation will begin at 1:40 p.m. (ET). A live we...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (Nasdaq: IBRX), a commercial-stage biotechnology company pioneering next-generation immunotherapies, today announced that its Founder, Executive Chairman, and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, will participate as a featured speaker at "Cancer 2035: A Roadmap for the Future," a landmark summit co-hosted by the Milken Institute and the Richard Nixon Foundation in Washington, D.C. on February 23–24, 2026. T...